NCT00357162View on ClinicalTrials.gov

Belinostat in Treating Patients With Myelodysplastic Syndromes

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
de Novo Myelodysplastic SyndromesPreviously Treated Myelodysplastic SyndromesSecondary Myelodysplastic Syndromes
Interventions
DRUG

belinostat

Given IV

Trial Locations (1)

55905

Mayo Clinic, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00357162 - Belinostat in Treating Patients With Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter